This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignees: The Wistar Institute, Crusade Laboratories Limited, University of Pennsylvania. Active years: 2008-2011.
Company Filing History:
3 out of 246 
2 out of 5 
1 out of 2,651 
Years Active: 2008-2011
Title: The Innovative Contributions of Nigel William Fraser
Introduction
Nigel William Fraser is a notable inventor based in Philadelphia, PA (US). He has made significant contributions to the field of cancer treatment through his innovative work with herpes simplex virus (HSV) mutants. With a total of 3 patents, Fraser's research focuses on developing new methods for combating melanoma and other cancers.
Latest Patents
Fraser's latest patents include groundbreaking treatments for melanoma using HSV mutants. One of his patents details the use of a mutant herpes simplex virus as an anti-cancer agent, specifically highlighting a modification in the γ34.5 gene in the long repeat region (R) that renders the gene non-functional. This innovative approach also encompasses the manufacture of medicaments and methods for testing cancer in mammals employing the HSV mutant. Another patent reiterates this concept, emphasizing the potential of HSV mutants in cancer treatment.
Career Highlights
Throughout his career, Fraser has worked with esteemed organizations such as The Wistar Institute and Crusade Laboratories Limited. His work in these institutions has allowed him to advance his research and contribute to the scientific community's understanding of cancer therapies.
Collaborations
Fraser has collaborated with notable colleagues, including Alasdair Roderick MacLean and Bruce Paul Randazzo. These partnerships have fostered a collaborative environment that enhances the development of innovative cancer treatments.
Conclusion
Nigel William Fraser's contributions to cancer research through his patents and collaborations highlight his commitment to advancing medical science. His innovative approaches to using HSV mutants represent a promising avenue for future cancer therapies.